Molecular genetic analysis of primary lung cancer and cancer metastatic to the lung

Anticancer Research

Volumn 19, Issue 2 A, 1999, Pages 1109-1115

  Schreiber, Gilbert ^a   Pitterle, Diana ^a   Kim, Young Chul ^a   Bepler, Gerold ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Lung cancer; Pulmonary metastasis

Indexed keywords

PROTEIN P53; RIBONUCLEOTIDE REDUCTASE;

CANCER INVASION; GENETIC ANALYSIS; HUMAN; LUNG CANCER; LUNG METASTASIS; MOLECULAR GENETICS; ONCOGENE RAS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TUMOR SUPPRESSOR GENE;

ALLELES; GENES, P53; GENES, RAS; HUMANS; LUNG NEOPLASMS; MUTATION; RIBONUCLEOTIDE REDUCTASES; SMOKING;

EID: 0032996268     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. Minna JD: The molecular biology of lung cancer pathogenesis. Chest 103: 449S-456S, 1993.
2. Woodhouse EC, Chuaqui RF, and Liotta LA: General mechanisms of metastasis. Cancer 80: 1529-37, 1997.
3. Bos JL: ras oncogenes in human cancer: a review [published erratum appears in Cancer Res 1990 Feb 15;50 (4): 1352]. CancerRes 49: 4682-9, 1989.
4. Khosravi-Far Rand Der CJ: The Ras signal transduction pathway. Cancer Metastasis Rev 13: 67-89, 1994.
5. Khosravi-Far R, Campbell S, Rossman KL, and Der CJ: Increasing complexity of Ras signal transduction: involvement of Rho family proteins. Adv Cancer Res 72: 57-107, 1998.
6. Mitsudomi T, Viallet J, Mulshine JL, Linnoila RI, Minna JD, and Gazdar AF: Mutations of ras genes distinguish a subset of non-small-cell lung cancer cell lines from small-cell lung cancer cell lines. Oncogene 6: 1353-62, 1991.
7. Rodenhuis S, van de Wetering ML, Mooi WJ, Evers SG, van Zandwijk N, and Bos JL: Mutational activation of the K-ras oncogenc. A possible pathogenetic factor in adenocarcinoma of the lung. N Engl J Med 317: 929-35, 1987.
8. Sugio K, Kishimoto Y, Virmani AK, Hung JY, and Gazdar AF: K-ras mutations are a relatively late event in the pathogenesis of lung carcinomas. Cancer Res 54: 5811-5, 1994.
9. Slebos RJ, Kibbelaar RE, Dalesio O, Kooistra A, Stam J, Meijer CJ, Wagenaar SS, Vanderschueren RG, van Zandwijk N, Mooi WJ, and et al: K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med 323: 561-5, 1990.
10. Rodenhuis S, Boerrigter L, Top B, Slebos RJ, Mooi WJ, van't Veer L, and van Zandwijk N: Mutational activation of the K-ras oncogene and the effect of chemotherapy in advanced adenocarcinoma of the lung: a prospective study. J Clin Oncol 15: 285-91, 1997.
11. Sugio K, Ishida T, Yokoyama H, Inoue T, Sugimachi K, and Sasazuki T: ras gene mutations as a prognostic marker in adenocarcinoma of the human lung without lymph node metastasis. Cancer Res 52: 2903-6, 1992.
12. Westra WH, Slebos RJ, Offerhaus GJ, Goodman SN, Evers SG, Kensler TW, Askin FB, Rodenhuis S, and Hruban RH: K-ras oncogene activation in lung adenocarcinomas from former smokers. Evidence that K-ras mutations are an early and irreversible event in the development of adenocarcinoma of the lung. Cancer 72: 432-8, 1993.
13. You M, Candrian U, Maronpot RR, Stoner GD, and Anderson MW: Activation of the Ki-ras protooncogene in spontaneously occurring and chemically induced lung tumors of the strain A mouse. Proc Natl Acad Sci USA 86: 3070-4, 1989.
14. Krontiris TG, Devlin B, Karp DD, Robert NJ, and Risch N: An association between the risk of cancer and mutations in the HRASI minisatellite locus [see comments]. N Engl J Med 329: 517-23, 1993.
15. Schreiber G, Fong KM, Peterson B, Johnson BE, KC OB, and Bepler G: Smoking, gender, and survival association with allele loss for the LOHIIB lung cancer region on chromosome 11. Cancer Epidemiol Biomarkers Prev 6: 315-9, 1997.
16. Chambers AFand Tuck AB: Ras-responsive genes and tumor metastasis. Crit Rev Oncog 4: 95-114, 1993.
17. Rak J, Mitsuhashi Y, Bayko L, Filmus J, Shirasawa S, Sasazuki T, and Kerbel RS: Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res 55: 4575-80, 1995.
18. Levine AJ: p53, the cellular gatekeeper for growth and division. Cell 88: 323-31, 1997.
19. Hainaut P, Hernandez T, Robinson A, Rodriguez-Tome P, Flores T, Hollstein M, Harris CC, and Montesano R: IARC Database of p53 gene mutations in human tumors and cell lines: updated compilation, revised formats and new visualisation tools. Nucleic Acids Res 26: 205-13, 1998.
20. Lee JM and Bernstein A: Apoptosis, cancer and the p53 tumour suppressor gene. Cancer Metastasis Rev 14: 149-61, 1995.
21. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA, Jr, Butel JS, and Bradley A: Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356: 215-21, 1992.
22. Greenblatt MS, Bennett WP, Hollstein M, and Harris CC: Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54: 4855-78, 1994.
23. Reichel MB, Ohgaki H, Petersen I, and Kleihues P: p53 mutations in primary human lung tumors and their metastases. Mol Carcinog 9: 105-9, 1994.
24. Kikuchi-Yanoshita R, Tanaka K, Muraoka M, Konishi M, Kawashima I, Takamoto S, Hirai H, and Miyaki M: Malignant transformation of rat embryo fibroblasts by cotransfection with eleven human mutant p53 cDNAs and activated H-ras gene. Oncogene 11: 1339-45, 1995.
25. Thompson TC, Park SH, Timme TL, Ren C, Eastham JA, Donehower LA, Bradley A, Kadmon D, and Yang G: Loss of p53 function leads to metastasis in ras+myc-initiated mouse prostate cancer. Oncogene 10: 869-79, 1995.
26. Nikiforov MA, Hagen K, Ossovskaya VS, Connor TM, Lowe SW, Deichman GI, and Gudkov AV: p53 modulation of anchorage independent growth and experimental metastasis. Oncogene 13: 1709-19, 1996.
27. Weber G: Biochemical strategy of cancer cells and the design of chemotherapy: GHA. Clowes memorial lecture. Cancer Res 43: 3466-92, 1983.
28. Elledge SJ, Zhou Z, and Allen JB: Ribonucleotide reductase: regulation, regulation, regulation. Trends in Biochemical Sciences 17: 119-23, 1992.
29. Reichard P: From RNA to DNA, why so many ribonucleotide reductases? Science 260: 1773-7, 1993.
30. Filatov D, Ingemarson R, Johansson E, Rova U, and Thelander L: Mouse ribonucleotide reductase: from genes to proteins. Biochemical Society Transactions 23: 903-5, 1995.
31. Stubbe J: Ribonucleotide reductases in the twenty-first century. Proceedings of the National Academy of Sciences of the United States of America 95: 2723-4, 1998.
32. Bepler G, O Briant KC, Kim Y-C, Schreiber G and Pitterle DM: High resolution physical map, contig, and genes in the centromeric region of chromosome segment 11p15.5. Genomics 55: 1-12, 1999.
33. Yang-Feng TL, Barton DE, Thelander L, Lewis WH, Srinivasan PR, and Francke U: Ribonucleotide reductase M2 subunit sequences mapped to four different chromosomal sites in humans and mice: functional locus identified by its amplification in hydroxyurea-resistant cell lines. Genomics 1. 77-86, 1987.
34. Fong KM, Zimmerman PV, and Smjth PJ: Correlation of loss of heterozygosity at 1 1p with tumour progression and survival in non-small cell lung cancer. Genes, Chromosomes and Cancel 10: 183-9, 1994.
35. Bepler G, Fong KM, Johnson BE, O'Briant KC, Daly LA, Zimmerman PV, Garcia-Blanco; MA, and Peterson B: Association of chromosome 11 locus DIIS12 with histology, stage, and metastases in lung cancer. Cancer Detection and Prevention 22: 14-9, 1998.
36. O'Briant KC. And Bepler; G: Delineation of the centromeric and telomeric chromosome segment 11p15.5 lung cancer suppressor regions LOH11A and LOH11B. Genes Chromosomes and Cancer 18: 111-4, 1997.
37. O'Briant K, Jolicoeur E, Garst J, Campa M, Schreiber G, and Bepler G: Growth inhibition of a human lung adenocarcinoma cell line by genetic complementation with chromosome 11. Anticancer Research 17: 3243-51, 1997.
38. Pitterle DM, O' Briant KC, and Bepler G: Genomic structure of the human gene for ribonucleotide reductase subunit M1 (RRM1) in the LOHIIA tumor suppressor region. Mammalian Genome, 1999.
39. Fan H, Huang A, Villegas C, and Wright JA: The R1 component of mammalian ribonucleotide reductase has malignancy-suppressing activity as demonstrated by gene transfer experiments. Proceedings of the National Academy of Sciences ofthe United States of America 94: 13181-6, 1997.
40. Zhou BS, Tsai P, Ker R, Tsai J, Ho R, Yu J, Shih J, and Yen Y: Overexpression of transfected human ribonucleotide reductase M2 subunit in human cancer cells enhances their invasive potential. Clinical & Experimental Metastasis 16: 43-9, 1998.
41. Wright JA, Alam TG, McClarty GA, Tagger AY, and Thelander L: Altered expression of ribonucleotide reductase and role of M2 gene amplification in hydroxyurea-resistant hamster, mouse, rat, and human cell lines. Somatic Cell and Molecular Genetics 13: 155-65, 1987.
42. Zhou BS, Hsu NY, Pan BC, Doroshow JH, and Yen Y: Overexpression of ribonucleotide reductase in transfected human KB cells increases their resistance to hydroxyurea: M2 but not M1 is sufficient to increase resistance to hydroxyurea in transfected cells. Cancer Res 55: 1328-33, 1995.
43. Fan H, Villegas C, and Wright JA: Ribonucleotide reductase R2 component is a novel malignancy determinant that cooperates with activated oncogenes to determine transformation and malignant potential. Proceedings of the National Academy of Sciences of the United States of America 93: 14036-40, 1996.